83.97 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||81.00 x 800|
|Ask||84.25 x 800|
|Day's Range||82.35 - 84.32|
|52 Week Range||59.60 - 85.92|
|PE Ratio (TTM)||113.63|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medidata (MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics. The combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest global pool of research data, companies’ own CRM data, 3rd party commercial data, and real-world data sources. Pharmaceutical, biotech, and medical device companies now have an unprecedented ability to manage and optimize value across the clinical and commercial continuum.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Healthcare Information Services stocks: Cerner Corp. (NASDAQ: CERN), Cotiviti Holdings Inc. (NYSE: COTV), Inovalon Holdings Inc. (NASDAQ: INOV), and Medidata Solutions Inc. (NASDAQ: MDSO).
Medidata announced that Memorial Sloan Kettering Cancer Center is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of genomic data and the application of artificial intelligence algorithms.
For the second consecutive year, Medidata will be presenting its pioneering analytics innovation during the 2018 ASCO Annual Meeting. The hour-long “Industry Expert Theater” session*, Integration of Genomics Data and Analysis in Oncology Research, will occur on June 2 at 9:30 AM CDT at the Oncology Professionals Hall, McCormick Place Convention Center in Chicago.
Biotech company, PhaseBio Pharmaceuticals, has become Medidata’s (MDSO) 1,000th customer. Medidata is the first and only eClinical company to achieve this milestone. PhaseBio intends to use the Medidata Clinical Cloud® for the initial Phase I study of its newest clinical development program for treatment of an orphan cardiopulmonary disease.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gartner, ...
Heart disease is the leading cause of death for both men and women. In partnership with the American Heart Association, Medidata (MDSO) is holding its first annual ‘Global Heart Health Awareness’ week to provide employees around the world with activities that inspire healthier living. Medidata is dedicated to supporting both its employees and the research community on the mission to eradicate heart disease.
Medidata today announced that Tarek Sherif, chairman and chief executive officer, will present at the 46th Annual J.P. Morgan Global Technology, Media and Communication Conference on Wednesday, May 16, 2018, at 3:00 p.m.
To help organizations mitigate the risk of regulatory non-approval and delays, Medidata Solutions is transforming how clinical trial data is validated prior to FDA submission with Edge Trial Assurance.
Medidata (MDSO) is pleased to announce that its director of strategic accounts and medical device/diagnostic sales, Melinda Pautsch, has been named a 2018 “Rising Star” by the Healthcare Businesswomen’s Association (HBA). In her role, Pautsch leads the team responsible for bringing the company’s transformative technologies to mid-sized biotech and medical devices and diagnostics (MD&D) organizations. Under Pautsch’s leadership, her team conducted several innovative projects, including the introduction of mobile health technology to a large device manufacturer to better track patient outcomes.
Medidata today announced that Rouven Bergmann, chief financial officer, will present at the Jefferies 2018 Global Technology Conference on Wednesday, May 9, 2018, at 2:30 p.m.
Medidata today announced that Idera Pharmaceuticals, Inc. , expanded its use of the Medidata Clinical Cloud® to automate operations, increase efficiencies, and gain better data visibility in order to accelerate their 2125 oncology development program.
Medidata is pleased to announce that its risk based monitoring solution, Edge Strategic Monitoring, won an Informa Clinical and Research Excellence Award, marking the third consecutive year the company earned this distinction.
NEW YORK, NY / ACCESSWIRE / April 19, 2018 / Medidata Solutions, Inc. (NASDAQ: MDSO ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 19, 2018 at 8:00 AM Eastern ...
Medidata , the leading global provider of cloud-based technology and data analytics for clinical research, today announced that it will release its first quarter 2018 financial results before the open of the market on Thursday, April 19, 2018.
Medidata announced that the National Health and Medical Research Council Clinical Trial Centre , University of Sydney, will now use Medidata’s unified platform and analytics for all major new studies starting in 2018.
Medidata successfully hosted NEXT conferences in Basel and Frankfurt, with executives from global life sciences and pharmaceutical companies presenting, including Bayer, Cancer Research UK, and Roche.
Oncology is leading the precision medicine revolution, as clinical researchers leverage and identify biomarkers to target patient subsets with more effective treatments, and the promise of improving Phase I success rate probability by three times 1.
Stock Monitor: Medical Transcription Billing Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free earnings report on Medidata Solutions, Inc. ...
Medidata today announced that Tarek Sherif, chief executive officer, and Rouven Bergmann, chief financial officer, will present at the Morgan Stanley Technology, Media & Telecom Conference on Wednesday, February 28, 2018, at 11:15 a.m.
Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS to support its clinical trial operations, in ophthalmology, across Japan, Asia, USA and the EU.
Medidata today announced that eClinical Solutions LLC, an industry-leading provider of end-to-end data management services and cloud based products for clinical data optimization, is expanding their technology partnership to further improve clinical trial processes and help life sciences researchers deliver innovative therapies to patients with the adoption of Rave Imaging.
Medidata has been named to Barron’s first annual list of the “100 Most Sustainable Companies” in the U.S., demonstrating the company's positive impact in five categories: shareholders, employees, customers, community and planet.